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Abstract
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tubercu-
losis (MTb). TB causes mortality of millions of people every year. Mycobacterium 
bovis Bacillus Calmette Güerin (BCG) is the only officially approved vaccine that 
protects against miliary TB and children but fails to protect in adulthood presum-
ably because of the lack of long lasting immunological memory. The problem is 
even more aggravated because of the emergence of multidrug-resistant strains. 
Therefore, immunogenetics and immunotherapy of antimycobacterial immunity 
are complex and poorly characterized. However, several studies either in the mouse 
model or in vitro, using derived dendritic or macrophages derived from PBMCs or 
human cell lines, have shown that Th1 type cellular immune response represented 
by IFN-γ, IL-12 in conjunction with IL-17, and IL-23 are key players of the immune 
protection to M. tuberculosis. It is known that under different settings type I IFNs 
promote bacterial virulence and disease exacerbation, since a study with active TB 
patients was concomitant with a dominant neutrophil-driven interferon inducible 
gene pattern. Furthermore, in an independent cohort of TB patients, ex vivo experi-
ments with BMDCs (bone marrow–derived dendritic cells) and myeloid from lung 
showed that there is a cross action between the components of IL-1β, eicosanoid 
pathways (prostaglandin, lipoxins, and leukotrienes) in active TB, while excessive 
type I IFNs and IL10 induction, concomitant with an inhibition of iNO3 and pros-
taglandin, could be found. These responses could be used as a therapeutic target 
instead of any other treatment based on antibiotics. Furthermore, the work from us 
has demonstrated that interferon alpha plus BCG vaccine protects against mycobac-
terial infections through modulating the Th1-type cellular immune response, iNOs, 
and IL-1β production. These immunomodulatory properties of interferon alpha 
could influence the outcome of the innate and acquired host immune responses in 
tuberculosis. 
Keywords: type I IFNs, adjuvants, mycobacterial infections, BCG vaccine,  
Th1-type cytokines, IL17, iNOS3
1. Introduction
Tuberculosis is the most serious cause of mortality after HIV/AIDS [1, 2]. 
Until now, BCG is the only officially approved vaccine that protects against 
miliary TB in children but it fails to protect in adulthood [1–3]. Therefore, the 
search for subunits agents that can boost primarily the central memory is still 
an issue of intense research worldwide [1, 2]. Several candidates have been 
developed and are under clinical studies [4–8]. Type I IFNs emerge, thus, as a 
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potential candidate adjuvant in bacterial infections. More than half century ago, 
interferons were first described like an antiviral “activity” [9–12]. Later on, they 
were recognized as innate inflammatory cytokines, and considered to be major 
connector of the innate and adaptive immunity. In general, type I IFNs could 
be considered like pleiotropic cytokines that belong to a multigenic family as 
outlined in Table 1 [11, 12].
Plasmacytoid dendritic cells (pDCs) are known to be major producers of type 
I IFNs producing up to hundred to a thousand times more IFNs-α than other 
cell types [13, 14]. To be produced, a recognition between pathogen-associated 
molecular patterns (PAMPs) on the pathogen surface (viral and bacterial), Toll-
like receptors (TLRs) (bacterial), with the pattern recognition receptor (PRRs), 
antigen-presenting cells (dendritic cells and macrophages) is necessary; followed 
by the activation of Myd88, interferon regulatory factor 3 (IRF3), IRF5 and IRF7 
(IFN-α), and NFκβ [13, 15]. Except leucocytes (which produce primarily IFN sub-
types), all cells are capable of detecting intracellular PAMPs and producing IFN-β 
following activation of IRF3 and NF-κβ [14, 16]. After viral or bacterial infec-
tions, there is an increase in the IFNs production in different types of cells. The 
functions in vivo of type I IFNs are the activation of DCs (dendritic cells), critical 
antigen-presenting cell for initiating immunity [13], in fact, type I IFN-treated 
DCs prime T cells in vitro promote the expression of costimulatory molecules [15], 
stimulate human blood monocytes differentiation into DCs [15]. Regardless of 
its role as an antiviral agent [11, 12], type I IFNs are also able to enhance adaptive 
immunity. A huge body of studies have shown type I IFNs immunomodulatory 
properties either to virus as well as to bacteria infections [12–15]. We think in 
agreement with other groups that type I IFNs have a strikingly dichotomy behav-
ior, since their actions can be either positive or negative depending on the settings 
and the surrounding scenery that will strongly influence the outcome of the host 
immune response.
Table 1. 
The multigenic family of type I IFNs in nature.
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2. The type I IFNs in nature
As outlined in Table 1, several human type I IFNs are already known to be 
selectively produced in a tissue-specific. As a multigenic family, type I IFNs, in 
particular, IFN-alpha, are comprised of 13, while IFN-β, IFN-ε (genital tract), IFN-κ 
(keratinocytes), and IFN-ω are only coded for a single gene. For the signalization to 
be carried out, there are basically two main steps that are common to the 17 IFNs. 
First is the binding to and signal through a shared heterodimeric receptor complex 
composed of a single chain of IFNAR1 and IFNAR2, which is present in almost on 
all nucleated cells [13–15]. Second, a signal is propagated within the cell via the JAK-
STAT signaling pathway [13–15]. This is also common to type III IFNs. As occurred 
in other interaction receptor-ligand, there are low or high affinity binding, and this 
could impact in the stability and the variety of the complex formed and therefore in 
the outcome of the host response [13–15]. This point has been the focus of intense 
research, because many questions arise for this interaction. Thus, for example, it 
is intriguing: why some interferons signal through the same receptor? Is there a 
redundancy of the immune system or is tailoring for each type of pathogen? Is the 
molecular evolution that has an impact also in the transcriptional gene printing, or 
in the adjuvant activities?
One of the hallmarks of the IFN action in nature is its immunomodulatory 
behavior [7, 10, 17]. These include among others the role of type I IFNs in the 
connection of innate and adaptive immune responses, such as B activation for 
enhancement of Ab responses [7, 10, 18], promotion of Th1 responses in terms of 
IgG2a Ab production, and CD4 + T cells activation and induction of an in vitro 
and in vivo differentiation of monocytes into functionally active DC [8, 19, 20], 
NK and T cytolytic activity, upregulation of histocompatibility antigen class 
I expression, induction of proliferation, and long-term survival of memory 
CD8 + T cells [7, 19, 20].
3. Is there any specificity in the type I IFN induction?
At glance yes, it would seem that there is specificity in the type I IFNs induc-
tion. As highlighted above, type I IFNs induction is a consequence of the host-
pathogen interaction [10, 16]. Thus, while membrane-bound PRRs are endowed 
with the ability to recognize viral or bacterial PAMPS (located in the cell surface, 
and within endosomal compartments [20]), it could be possible that the expres-
sion profile of each cell type in particular of these PRRS on the innate immune 
cells that could potentially give rise to specificity in IFN subtype production—an 
early step during infection inward ultimately fine-tuning the immune response— 
an issue that is challenging because to measure the different profiles of IFN-α 
for each cell type has enormous limitations under physiological conditions, but 
it is true that should be pinpointed whether the IFN responses are qualitatively 
different in response to distinct pathogens [9, 20]. Furthermore, IFN-β and/or 
the IFN-α subtypes signal through TLRs (TLRs are membrane-bound compart-
ments) of cosmopolitan expression in different human cells, which can potentially 
give some specificity to the interaction. Thus, it is known from the literature that 
TLR3, TLR7, TLR8, and TLR9 recognize viral nucleic acids [9, 10, 16]. Another 
type of receptor, specialized in detecting pathogen-derived RNA in the cyto-
plasm, that is also involved in the production of IFN-β in nonimmune cells, is 
the members of the RIG-I-like receptors (RLRs), a family of cytoplasmic RNA 
helicases important for host viral responses and includes retinoic acid-inducible 
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gene I (RIG-I)-melanoma differentiation-associated protein 5 (MDA5) and the 
laboratory of genetics and physiology-2-(LGP3). The signalization through these 
receptors initiates via these intracellular PRRS set in motion a series of events 
that has resulted in IRF3 and NF-κβ activation, both of which are required for the 
production of IFN-β and the release of chemokines that recruit immune cells to 
the site of infection [7, 9, 16].
4.  How type I IFNs become central players in the connection between 
innate and acquired immune response
Type I IFNs are the dominant player of the connection between the innate and 
adaptive immune responses through the main interaction with antigen-present-
ing immune cells, such as dendritic cells (DCs), in particular, with plasmacytoid 
dendritic cells (pDCs) [6, 18, 21], which are precisely the major producers of type 
I IFNs producing up to a hundred to a thousand times more IFNs-α than other 
cell types [13, 14]. This is supported from in vitro experiments that have shown 
that type I IFN-treated DCs prime T cells in vitro more  effectively [11, 12, 15].
5. How to calibrate host immune response to bacterial infections?
Calibrating host immune system for bacterial infections initiated as outlined 
above through the surface membrane conserved molecules organized in “patterns” 
such as peptidoglycan (PGN), lipopolysaccharide (LPS), and nucleic acid structures 
or pathogen-associated molecular patterns (PAMPs). Whereas, innate cells have the 
counterpart, “PRRS” (pattern recognition pathogen) [8, 10, 16], that automatically 
unlock the unspecificity of the type I IFNs production, the recognition of the “self” 
versus “nonself” [9], one PRRS for a particular type of PAMPs either bacterial, 
fungal, or virus; followed by a more general signalization route through Myd88 
and IRFs (this could be also specific for each type of IFNs), and finally, NF-κβ 
translocation to the nucleus and thus IFNs production [8–10]. The synthesis of type 
I IFNs is not the job of a specialized cell type. However, an important distinction 
must be made between those cells that produce just enough type I IFNs to affect the 
local environment, and those produced by IFN-producing cells (IPCs) which could 
contribute to connect innate and adaptive immune responses more effectively. How 
much is produced or how much should be produced depends mostly on the tissue 
involved and the signal received, in particular, viral, bacterial [6, 18, 21]. Therefore, 
it is intriguing that all IFN-α proteins interact with the same receptor complex and 
have a spectrum of distinct effects, that goes from the specific antiviral capacity of 
individual IFN-α to differences in the activation of natural killer (NK) cells [16, 17]. 
Trying to understand why some types of IFNs, one temptative explanation could be, 
different temporal or spatial regulation of their expression, which might impact in 
the molecular calibration of the host immune response to viral or bacterial infections 
since TLR signaling targets (such as NF-κβ) and IFNAR signaling targets (such as 
STAT) converge at their promoters [10, 16]. Thus, it seems possible to think that it 
is the TLR4 signaling that arises as a key player for type I IFNs production by dif-
ferent cell types in response to Gram-negative pathogens. Several studies have in 
addition highlighted this point, some has been concentrated in the LPS effect [8, 16] 
on the type I IFNS induction, while others have focused in the gene that encode 
inducible oxide nitric synthase (iNOS), which is more evident once a bacterial signal 
through TLR, as demonstrated with Chlamydia spp. [8, 16]. Despite this gap in our 
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knowledge, the gene encoding iNOs is a paradigm for antimicrobial genes requir-
ing type I IFN synthesis and expression downstream of TLR, implying a potential 
important role of type I IFN synthesis during nonviral infection. More recent 
infection studies that have investigated the mechanism behind this type I IFN 
effect demonstrated its importance in generating TNF-α, Il-1β, or bacterial signals 
(Chlamydia spp). IL-12-independent cellular immunity to S. typhimurium. This was 
attributed to the ability of type I IFNs to stimulate STAT-4 tyrosine phosphoryla-
tion in NK cells and Th1 cells. Together with IL-18 signals, this triggers expression 
of the IFN-alpha gene [8, 16]. In addition, it has been described that the induc-
tion of intrinsic immunity to kill bacteria or prevent their invasion and the 
regulation of chemokines, proinflammatory cytokines, and phagocytic cells. The 
mechanism by which IFN-α/β promotes host protective responses or susceptibility 
in bacterial pathogens is poorly defined and the factors that determine whether a 
response will be protective or pathogenic are not yet fully understood. However, it 
is well known that type I IFNs that are released during bacterial infection by IFN-
producing cells (IPDCs) can cause the activation of signal transducer and activator 
of transcription 4 (STAT 4) in natural killer (NK) and T helper (TH1 cells) [5, 8, 
10, 16]. In conjunction with interleukin 18 (IL-18)-derived signals, STAT-4 stimu-
lates the expression of the IFN-alpha genes, which provide antibacterial immunity, 
such as macrophage activation [22, 23]. In addition, type I IFNs make important 
contributions to the maturation and activation of dendritic ells (DCs) [24], and in 
this way, influence antigen presentation, T cell activation, and the development of 
adaptive immune responses.
6. Dichotomy in the type I IFNs’ action in bacterial infections
In contrast to viral infections, IFN-α/β can be protective or can have detrimental 
effects for the host during bacterial infections in a bacterium-specific manner, 
although less is known about the role of these. By one side, IFN-α/β-mediated 
signaling primes the production of interleukin-10 (IL-10), proinflammatory 
cytokines, and antimicrobial effector mechanism. But, IL-10 mediates a negative 
feedback loop, suppressing the production of proinflammatory cytokine, includ-
ing IL-12, tumor necrosis factor (TNF), and IL-1 α/β cytokines that are key in the 
host resistance to bacterial infections. Moreover, some studies have addressed to 
decreased bacterial load and/or improved host survival in the absence of IFN-
α/β-mediated signaling. Thus, for example, IFN-α/β contributes to priming the 
host to clear the virus, while increasing host susceptibility to bacterial assault. 
Interestingly, under this scenario, IFN-α/β produced in response to infections is 
damaging to the host but would normally be protecting during a primary infection, 
i.e., S. pneumoniae or E. coli [8, 10, 16]. This would imply that the circumstances 
of IFN-α/β production and action are crucial to determine host protection versus 
pathogenesis and highlight also the dichotomy role of IFN-α/β depending on the 
pathogen. These different issues have been pinpointed and clearly showed that, for 
example, on mycobacterial infections, there is a detrimental effect of type I IFNs 
in active TB patient, which showed in blood a remarkable transcriptional gene 
expression profile in neutrophils that correlated with extensive lesion in lung [25]. 
In a different cohort of patients from Africa, it was also found that this same result, 
the broad signature of IFN-α/β, could be found anywhere [25]. These findings 
have revealed the dark side of these cytokines that is—the ability to suppress host 
immune protective response by downregulating the Th1-type cellular immune 
responses (IFN-gamma IL12 production), iNOS3 synthesis while inducing IL-10. In 
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summary, favorable or unfavorable effect can be determined by the infecting strain, 
the severity of infection, the stage of infection, and the interplay among the differ-
ent immune effector mechanisms.
7. Signalization pathways of type I IFNs as an adjuvant
Adjuvants can stimulate innate immunity by interacting with specialized pat-
tern recognition receptors (PRRs) including Toll-like receptors (TLRs) [26, 27]  
and nucleotide-binding oligomerization domain receptors [28]. These PRRs are 
immersed in the membrane surface of the antigen presenting such as DCs or 
macrophages, even in epithelial and B cells. Once this interaction is initiated, it 
is followed by serial reactions that lead to the production of proinflammatory 
cytokines and chemokines that will influence drastically the outcome of the host 
immune response. The shape of this response will be affected by initial stimulus, 
and therefore, the antigen-presenting cells (M1, M2) as well as the T cell popula-
tion will adopt a state of differentiation (Th1/Th2/Th3) [29]. However, many cell 
types, including nonhematopoietic cells, express PRR and produce cytokines dur-
ing innate immunity [30]. In conjunction, adjuvant action could be viewed as the 
contribution of cytokines milieu and the different cellular sources of them in order 
to initiate and potentiate immunity from the native polyclonal repertoire cells and 
molecules.
The role of IFN-I as natural immune adjuvants for commercial vaccines [18, 21, 31]  
was established by showing that either mucosal or intramuscular administration 
of influenza virus antigen-admixed IFN-I to mice enhances viral resistance and 
increased production of antiviral Ab [18, 21]. The adjuvant activity of IFN-I leads 
to potentiate the adaptive immune response by directly stimulating lymphocytes 
or activating DC that represents the critical antigen-presenting cells governing the 
fate of helper T cell responses [18, 21, 24, 25]. The immunity-promoting activity of 
IFN-I can result from a direct effect on T cells. In this situation, IFN-I acts as “third 
signal” of activation, helping to sustain survival of proliferating cells. IFN-I also 
supports Th1 differentiation, activation of STAT-4 signaling, and IFN-γ production 
[24, 25]. These activities are reminiscent of the biological effects of IL-12 and could 
have a role in the observed adjuvant type I IFN activities. Indeed, the variable need 
for IFN-I to act directly on T cells during activation and differentiation may thus 
arise from a similarly variable production of IL-12.
8.  How type I IFNs shape the host immune system to antimycobacterial 
infection?
Despite the wealth of studies, shaping the host immune response to bacterial 
infection is complex and still remains to be characterized. Type I IFNs can shape the 
antimycobacterial immunity by enhancing action of dendritic cells and monocytes, 
by promoting CD4+ and Cd8 T cell responses, by enhancing NK cell responses and 
B cell responses [8, 10, 16, 18, 21]. Type I IFNs (IFN-α/β) have a direct effect on the 
maturation of DCs, through increasing cell surface expression of MHC molecules 
as well as costimulatory molecules such as CD80 and CD86, leading to an aug-
mented activation of T cells. Another effect of type I IFNs (IFN-α/β) is to promote 
the migration of DCs to lymph nodes through upregulating chemokine receptor 
expression thus promoting T cell activation. Moreover, direct downregulation of 
IFN-γR expression may not be the central mechanism by which IFN-αβ exerts their 
effects on IFN-γ activity [7–10, 18, 21–23], instead, in both mouse and human cells, 
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it has been shown that IFN-αβ potently suppresses the ability of macrophages to 
upregulate antimycobacterial effector molecules and to restrict bacterial growth, in 
response to both M. leprae and M tuberculosis. The importance of this mechanism of 
action of IFN-αβ is further suggested by experiment using Ifngr 1-/- or Ifnar1-/-  
mice, which suggests that IFN-αβ contributes to host protection in the absence of 
the IFN-γ pathway [16, 17, 22, 23]. In another study, it was observed a natural muta-
tion in the gene ISG15 in humans that conferred host-protective response mediated 
by type I IFNs (IFN-αβ) to M. tuberculosis infection [23]. No further studies were 
made. Similarly, it has been reported that IL-12p70 suppressed type I IFNs (IFN-αβ) 
during M. tuberculosis infection [27, 28, 32]. This suppression could result from the 
presence of IL-10, the downregulation of IFN-γR, and/or the induction of negative 
regulators of IFN-mediated signaling such as protein arginine methyltransferase-
1(PRMT1) [9, 10, 21, 22]. Finally, IFN-αβ, possibly by influencing chemokine 
expression, has been shown to be involved in the generation and trafficking of M. 
tuberculosis permissive innate cells to the lungs in a mouse model thus contributing 
to the exacerbation of infection [8, 9, 26, 31, 32].
Several human clinical studies have obtained favorable assessment of using 
aerosolized IFN-α as adjuvant therapy for patients with tuberculosis [33]. 
However, it has been shown that there is a TB reactivation during IFN-alpha 
treatment for hepatitis D infection [33]. In a different study, it has been also dem-
onstrated that in active TB patients, there is a correlation between the extent of 
lung lesion with the transcriptional signature of type I IFNs in blood, in particu-
lar, in neutrophils [25]. This was also found in a cohort of Africa and Indonesia.  
These findings implied that the type I IFNs are common broad signature and 
strengthened the role of these cytokines in the pathogenesis of TB [8, 9, 25, 26, 34]. 
Indeed, seminal work by Giacomini et al., [24] have demonstrated that IFN-β 
improves M. bovis BCG vaccine immunogenic capacity by exerting a strong 
influence of DCs maturation, throughout enhancing costimulatory molecules 
such as CD86, CD83, and therefore, increased IL-12 which will act on macrophage 
killing activities [18, 20, 29, 30]. Later on, further studies by Mayer-Babier et al. 
[34] have demonstrated that the action of type I IFNs in tuberculosis could reside 
in the pathways of IL-1β, arachidonic acids, prostaglandins, and iNOs. Active 
TB patients showed an increased production of these molecules. This constitutes 
the first cue for a clinical therapeutic target of TB [34]. In more recent work by 
us, we found that type I IFNs action, in particular, interferon alpha, could exert 
its action in conjunction with M. bovis BCG vaccine that potentially could be 
signaling through Toll-like receptor and/or tentative through IFN-R1, leading to 
a protective antimycobacterial immune response, i.e., Th1-type cytokines and so 
far to IL-17 and IL23 production [35–37].
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